Stock listing

OTC:KLDO Kaleido Biosciences, Inc. Stock

Follow Kaleido Biosciences, Inc. into a list and get an email when it puts out news.

Share price · OTC:KLDO

$0.0001 USD 0.0000 (0.0%)

Close on Nov 20, 2026

Past year 0.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.0001 – $0.0001 USDNov 20, 2026
Volume
3,064 sharesNov 20, 2026
Market cap
$4,262 USDAt the close on Nov 20, 2026 · price × 42.62M shares outstanding
52-week range
$0.0001 – $0.2000 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$0 USDMedian day 200 shares · 26 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Kaleido Biosciences, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:KLDO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00010.00000.0%$0.0001$0.0001$0.00013,064
$0.00010.00000.0%$0.0001$0.0002$0.0001824
$0.00010.00000.0%$0.0001$0.0001$0.00011,600
$0.00010.00000.0%$0.0001$0.0001$0.0001200
$0.00010.00000.0%$0.0001$0.0001$0.00011,075
$0.00010.00000.0%$0.0001$0.0001$0.00014,020
$0.00010.00000.0%$0.0001$0.0001$0.00014,496
$0.00010.00000.0%$0.0001$0.0001$0.000121,615
$0.00010.00000.0%$0.0001$0.0001$0.00011,200
$0.00010.00000.0%$0.0001$0.0001$0.00011,700
$0.00010.00000.0%$0.0002$0.0002$0.00011,700
$0.00010.00000.0%$0.0001$0.0001$0.00012,500
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001715
$0.00010.00000.0%$0.0001$0.0001$0.00011,641
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001670
$0.00010.00000.0%$0.0001$0.0001$0.00011,222
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.000111,167
$0.00010.00000.0%$0.0001$0.0001$0.0001200
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001525
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00011,500
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0100$0.00012,740
$0.00010.00000.0%$0.0001$0.0001$0.000114,742
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001202
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001220
$0.00010.00000.0%$0.0001$0.0001$0.0001100
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001140
$0.00010.00000.0%$0.0001$0.0001$0.0001940
$0.00010.00000.0%$0.0001$0.0001$0.0001400
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001653
$0.00010.00000.0%$0.0001$0.0001$0.00012,679
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00012,312
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001260
Ticker
OTC:KLDO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

Kaleido Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
Decks
9 decks · latest Oct 5, 2021

Valuation

price Nov 20, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
0.00

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Kaleido Biosciences, Inc. · OTC:KLDOUS$4,262n/an/an/an/an/an/an/a0.00
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
GlucoTrack, Inc. · NASDAQ:GCTKUS$217,049−US$887,951n/an/an/an/an/an/a1.73
Regen BioPharma, Inc. · OTC:RGBPUS$167,528US$167,289n/a0.7×n/an/a−501.4%n/a1.20
CNBX Pharmaceuticals Inc. · OTC:CNBXUS$160,577US$151,090n/an/an/an/an/an/a1.78
Fifty 1 Labs Inc. · OTC:FITYUS$118,532US$282,021n/a6,000×n/an/an/an/a-1.17
GB Sciences, Inc. · OTC:GBLXUS$81,414US$2.07Mn/an/an/an/an/an/a-0.46
Lyra Therapeutics, Inc. · OTC:LYRAUS$53,246US$14.42Mn/a36.2×n/an/an/an/a0.67
ZyVersa Therapeutics, Inc. · OTC:ZVSAUS$810US$1.20Bn/an/an/an/an/an/a-0.56
Median of the othersUS$164,053US$159,19018.5×0.1×−382.1%1.3×1.14

Events

QuarterResults
Quarter to Jun 30, 2022Aug 10, 2022
Q1 2022Apr 1, 2022 · Before open
Q4 2021Mar 29, 2022
Q3 2021Nov 1, 2021 · Before open
Q2 2021Aug 11, 2021 · Before open
Q1 2021May 4, 2021 · Before open
Q4 2020Mar 3, 2021 · Before open

Open Events

Decks

DeckKindSlidesDate
Investor Day (October 2021)Investor day40 slidesOct 5, 2021
Investor Presentation (June 2021)Investor deck38 slidesJun 17, 2021
Technical Presentation (March 2021)Technical21 slidesMar 24, 2021
Investor Presentation (January 2021)Investor deck38 slidesJan 20, 2021
Investor Presentation (May 2020)Investor deck43 slidesMay 14, 2020
Investor Presentation (December 2019)Investor deck32 slidesDec 12, 2019
Investor Presentation (October 2019)Investor deck29 slidesOct 30, 2019
Investor Presentation (August 2019)Investor deck30 slidesAug 1, 2019
Investor Presentation (April 2019)Investor deck31 slidesApr 8, 2019

Open Decks

Financials

Annual, in USD

Income statement

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.10M975.0K0000
Cost of revenue2.36M56.0K1.32M000
Gross profit-1.25M975.0K-1.32M000
Research and development67.8M56.0M64.2M42.1M21.0M7.86M
Selling, general and administrative21.0M23.9M22.4M18.6M6.04M1.57M
Operating income-87.7M-78.9M-86.7M-60.7M-27.0M-9.44M
Depreciation and amortization228.5K2.36M1.82M1.32M792.0K316.0K99.0K
EBITDA-85.3M-77.1M-85.3M-59.9M-26.7M-9.34M
Interest expense2.84M2.80M977.0K1.00M435.0K141.0K
Income before tax-90.3M-81.6M-86.3M-61.7M-27.6M-9.69M
Income tax2.98M-1.82M-1.32M-56.0K-94.0K139.0K
Net income-90.3M-79.8M-85.0M-61.7M-27.6M-9.69M
Earnings per share, basic-2.16-2.39-3.31-2.10-1.23-0.43

Balance sheet

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents38.5M46.2M71.2M76.1M28.5M2.73M
Receivables934.0K5.00K45.0K1.50M
Current assets42.3M48.7M73.3M76.2M28.6M4.36M
Property, plant and equipment5.67M8.46M6.74M4.69M1.98M513.0K
Total assets50.1M59.3M82.3M85.3M30.7M4.99M
Accounts payable5.67M5.39M2.02M3.44M864.0K872.0K
Current liabilities29.7M16.7M10.4M11.3M3.85M1.21M
Long-term debt5.55M18.4M20.4M14.8M14.8M4.95M
Total debt21.7M21.0M20.5M14.9M14.9M4.95M
Total liabilities39.5M38.8M33.4M27.1M74.4M21.9M
Shareholders' equity10.6M20.5M48.9M58.2M-43.7M-16.9M
Shares outstanding41.9M41.9M33.5M25.7M29.4M22.4M22.4M

Cash flow

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-77.1M-61.5M-75.8M-46.3M-22.5M-9.35M
Capital spending0-1.13M-4.02M-3.59M-3.00M-1.41M-195.0K
Free cash flow-78.2M-65.5M-79.4M-49.3M-23.9M-9.54M
Cash from investing-691.0K-4.02M-3.59M-3.00M-1.41M-195.0K
Cash from financing70.0M40.4M74.6M98.9M49.7M10.9M
Share buybacks-33940.5M68.4M100.9M39.9M5.99M
Change in cash-7.75M-25.1M-4.74M49.6M25.8M1.39M

Open Financials

Cap table

Built by 6ix from Kaleido Biosciences, Inc.’s releases

Common shares
42,622,559
Fully diluted
42,622,559

Fully diluted

LineShares
Common shares42,622,559

Share count over time

CountShares
Nov 22, 202642,622,559

Open Cap table

Shareholders

HolderSharesOf the companyAs of
Bay Harbor Wealth Management, LLC2,300<0.01%Sep 30, 2026
Hantz Financial Services, Inc.350<0.01%Sep 30, 2026
RMG Wealth Management LLC70<0.01%Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anne Prener
Other companies: Keros Therapeutics, Inc. (Director · Since at least Jun 25, 2026); Damora Therapeutics, Inc. (Director · Since at least Jan 8, 2021); Rubius Therapeutics Inc (Director · May 12, 2021 – May 12, 2022 · Past)
Director · Jun 30, 2021 – Jun 30, 2021 · Past
John Sculley
Other companies: Celularity Inc. (Director · Jul 16, 2021 – Jun 14, 2023 · Past); Zeta Global Holdings Corp. (Director · Jun 9, 2021 – Jun 9, 2025 · Past); Decoy Therapeutics Inc. (Director · Jan 28, 2015 – Jun 8, 2016 · Past)
Director · Feb 27, 2019 – Feb 27, 2019 · Past
Joshua Brumm
Other companies: Crescent Biopharma, Inc. (Chief Executive Officer · Since at least Jun 13, 2025); Dyne Therapeutics, Inc. (CEO & President, Director · Sep 16, 2020 – Mar 8, 2024 · Past); Aravive Inc (COO and CFO · Nov 12, 2015 – Oct 19, 2017 · Past)
See Remarks · Feb 27, 2019 – Mar 4, 2019 · Past
Geoffrey von Maltzahn
Other companies: Sana Biotechnology, Inc. (Director · Feb 3, 2021 – Feb 8, 2021 · Past)
Director · Feb 27, 2019 – Jun 30, 2021 · Past
Jean K Mixer
Other companies: NxStage Medical Inc (Director · Feb 21, 2019 – Feb 21, 2019 · Past)
Director · Sep 30, 2019 – Jun 30, 2021 · Past
Daniel L MenichellaChief Executive Officer, Director · Oct 13, 2020 – Jan 14, 2022 · Past
Vlieg Johan van HylckamaChief Scientific Officer · May 5, 2021 – Feb 28, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Kaleido Biosciences, Inc.